-$0.06 Earnings Per Share Expected for Catalyst Pharmaceuticals, Inc. (CPRX) This Quarter

Equities research analysts expect that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will announce ($0.06) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Catalyst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.05). Catalyst Pharmaceuticals also posted earnings per share of ($0.06) during the same quarter last year. The business is scheduled to issue its next earnings results on Tuesday, August 8th.

On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.22). For the next financial year, analysts expect that the firm will post earnings of ($0.23) per share, with EPS estimates ranging from ($0.33) to ($0.15). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.06).

Separately, Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.

Shares of Catalyst Pharmaceuticals (CPRX) opened at 3.05 on Friday. The stock has a 50 day moving average of $2.77 and a 200-day moving average of $1.87. The firm’s market capitalization is $255.55 million. Catalyst Pharmaceuticals has a one year low of $0.70 and a one year high of $3.20.

COPYRIGHT VIOLATION WARNING: “[[title]]” was first posted by [[site]] and is the property of of [[site]]. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at [[permalink]].

A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new position in Catalyst Pharmaceuticals during the first quarter worth approximately $746,000. Geode Capital Management LLC increased its position in Catalyst Pharmaceuticals by 0.3% in the first quarter. Geode Capital Management LLC now owns 462,677 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 1,446 shares in the last quarter. Vanguard Group Inc. increased its position in Catalyst Pharmaceuticals by 0.5% in the first quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock worth $5,865,000 after buying an additional 15,600 shares in the last quarter. Knott David M purchased a new position in Catalyst Pharmaceuticals during the first quarter worth approximately $554,000. Finally, JPMorgan Chase & Co. purchased a new position in Catalyst Pharmaceuticals during the first quarter worth approximately $155,000. Hedge funds and other institutional investors own 29.82% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com